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Background: Various medications of natural origin have effectively treated stress-related disorders, such as sleep
disturbances and agitated conditions. The efficacy of Neurexan, a multicomponent, low-dose medication, has been
demonstrated in observational studies, but its exact mechanism of action has not been determined.
Methods: To characterize the effects of Neurexan on the central nervous system, we analyzed the spectral
frequencies of field potentials in four rat brain areas after a single oral administration of Neurexan. Different doses
of Neurexan were tested within a crossover design, and effects were compared with vehicle control.
Results: Significant effects were observed with 0.5 tablets of Neurexan, predominantly on δ- and θ-waves in the
frontal cortex and reticular formation (P< 0.01). In the reticular formation, significant changes of δ- and θ-waves
occurred as early as during the first hour after administration. The time course revealed a significant and
longer-lasting increase of δ- and θ-waves in the frontal cortex and reticular formation, whereas other spectral
frequencies were only transiently affected in the frontal cortex, reticular formation, and striatum.
Conclusion: In conclusion, this study demonstrated that the low-dose medication Neurexan influences central
nervous system activity in rats. The resulting electroencephalographic profile of Neurexan shows several similarities
with those of other calming agents, such as Valeriana and Passiflora, suggesting a potential benefit of Neurexan for
patients with stress-related disorders. Moreover, this report demonstrates that electroencephalographic signatures
are also valid biomarkers for the assessment of low-dose medications, such as Neurexan.
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ElectroencephalographyBackground
Stress-related disorders, such as mild anxiety, nervous-
ness, and insomnia, are widespread among the popula-
tion. For example, the prevalence of anxiety disorders
and insomnia reaches 16.6% and 26%, respectively [1,2].
Currently used medications include benzodiazepines and
serotonin-specific reuptake inhibitors. However, these
medications can be accompanied by considerable ad-
verse effects, such as cognitive impairment and depend-
ency [3-5]. For the treatment of stress-related disorders,
self-medication is often practiced, and there is a strong
association between stress and alcohol consumption [6],* Correspondence: kerstin.roeska@heel.com
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reproduction in any medium, provided the orleading to the known potential consequences for phys-
ical and psychological health.
Clinical studies have documented that complementary
and alternative medicine effectively treats stress-related dis-
orders, such as sleep disturbance and anxiety-related condi-
tions, without serious adverse effects [7,8]. For example,
Neurexan is a multicomponent drug constituted of highly
diluted natural, mainly plant, extracts. It is recommended
to treat mild sleep disturbances and agitated conditions [9].
The effectiveness of the single components of Neur-
exan (passiflora incarnata [Passiflora], avena sativa, cof-
fea arabica, and zincum isovalerianicum) has been
demonstrated in human and animal studies. Three ran-
domized controlled trials demonstrated the anxiolytic ef-
ficacy of Passiflora as monotherapy [10,11] and as part
of an herbal combination [12]. Animal studies demon-
strated the sedative effects of avena sativa [13] andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cruda [14]. In a retrospective analysis, a potential benefi-
cial effect of zincum isovalerianicum in patients with
restless legs syndrome could be observed [15].
Although these components are less concentrated in
Neurexan than in the reference drugs tested in the pre-
viously mentioned studies, Neurexan is effective for the
treatment of moderate insomnia and nervousness. In
two observational studies, Neurexan was demonstrated
as a well-tolerated alternative to conventional valeriana
officinalis (Valeriana)–based therapies for the treatment
of moderate insomnia and nervousness [16,17].
As a multicomponent medication, Neurexan presum-
ably acts on different targets, and the resulting net effect
on the central nervous system has not been character-
ized. During the past decade, electroencephalography
(EEG) has provided surrogate measures of drug efficacy
of psychoactive drugs. The EEG signature obtained from
the spectra of oscillation frequencies may differ between
baseline and experimental conditions. Therefore, an
EEG signature might be seen as a biomarker [18].
Biomarkers are increasingly used to both predict the
clinical response to treatment and characterize the
mechanism of action [19]. For instance, changes of EEG
signatures observed after administration of experimental
compounds can be assigned to the interference of
drugs with certain neurotransmitter systems, such as the
cholinergic, dopaminergic, and noradrenergic systems
[20-23]. Moreover, different drug categories, such as
antidepressive, anticonvulsive, analgesic, neuroleptic,
stimulatory, narcotic, sedative, and hallucinogenic drugs,
result in a reproducible and disease-specific EEG signa-
ture. Therefore, unknown compounds could be classified
into distinct drug categories by discriminant analysis of
EEG data [24]. More important, the conservation of
brain structure and neurobiological features across mam-
malian species allows the translatability of results [18].
In this report, we asked if the multicomponent, low-
dose medication Neurexan induces an EEG signature
that explains its calming effects. To answer this ques-
tion, we characterized the effect of different doses of




Neurexan (Heel GmbH, Baden-Baden, Germany) is an
over-the-counter medication constituted of highly diluted
ingredients. One tablet consists of 0.6 mg passiflora incar-
nata D2, 0.6 mg avena sativa D2, 0.6 mg coffea arabica
D12, 0.6 mg zincum isovalerianicum D4, 1.5 mg magne-
sium stearate, and 300 mg lactose-monohydrate (D indi-
cates dilution). All components are prepared according to
the European Pharmacopoeia [25].Neurexan is recommended for the treatment of mild
sleep disturbances and agitated conditions [9]. In animal
experiments, Neurexan was dissolved in 0.9% NaCl
(1 mL/kg body weight). The applied doses of Neurexan
(0.25, 0.50, or 1 tablet per animal) correspond to the 6-
to 12-fold human equivalent dosage [26]. Neurexan or
vehicle controls (1 mL/kg 0.9% NaCl) were orally admi-
nistered as a single dose. Other drugs used as compara-
tors in discriminant analyses were described earlier [24].
Animals
Eight 8-month-old Fisher 344 rats (Charles River La-
boratories, Sulzfeld, Germany) were kept at the
preclinical study center (NeuroCode AG, Wetzlar,
Germany) in sterile filter-top cages on a reversed day-
night cycle and provided with food and water ad libi-
tum. Animal procedures were performed according to
German health guidelines and animal protection laws
and were approved by the Regional Commission
Gießen (GI 21/4-Nr.66-2009, Regierungspräsidium
Gießen, Schanzenfeldstraße 8, 35578 Wetzlar). For sur-
gery, animals were anesthetized with an intramuscular
injection of 10% ketamine hydrochloride (1 mL/kg).
Four concentric bipolar steel electrodes were then
implanted in the left hemisphere (3 mm lateral) by
stereotactic surgery. The anterior coordinates were
12.2, 5.7, 9.7, and 3.7 mm for the frontal cortex,
hippocampus, striatum, and reticular formation, re-
spectively [27]. A plate carrying four bipolar SNF100
neurological electrodes (Rhodes Medical Instruments
Inc, Summerland, CA), a 5-pin plug, and a transmitter
(26 × 12 × 6 mm; 5.2 g) was fixed on the skull by three
steel screws and dental cement.
EEG recording
For the recording of EEG signals, cages were placed in a
copper-shielded room. As described earlier, signals were
transmitted by a wireless radio-telemetric system
(Rhema Labortechnik, Hofheim, Germany) and pro-
cessed to give power spectra of 0.25-Hz resolution [28].
After automatic artifact rejection, signals were collected
in 4-second units and fast Fourier transformed using a
Hanning window. Sampling frequency was 512 Hz. Four
values were averaged to give a final sampling frequency
of 128 Hz, well above the Nyquist frequency. The result-
ing electrical power spectra were divided into δ-waves
(0.8-4.5 Hz), θ-waves (4.75-6.75 Hz), α1-waves (7.00-
9.50 Hz), α2-waves (9.75-12.50 Hz), β1-waves (12.75-
18.50 Hz), and β2-waves (18.75-35.00 Hz). Spectra were
averaged every 3 minutes. For further analysis, periods
of 60 minutes were averaged. To exclude circadian
effects, all measurements were performed at the same
time. During recording, rats were moving freely but
could not eat to avoid artifacts.
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The study began 2 weeks after surgery. Animals were
assigned to receive different doses of Neurexan or ve-
hicle control in a crossover design. All eight animals
were exposed to one dose per experiment and then
received a different dose after a 1-week washout period.
In each experiment, a single dose of Neurexan or vehicle
control was administered orally after a predrug baseline
recording for 45 minutes. Then, after a 5-minute interval
for recovery, EEG signals were recorded for 5 hours.
Statistics
The EEG signals (in μV2) were documented in hourly
intervals as percentage of baseline signals. Each of the
six frequency bands within each brain region was mea-
sured, and the data of eight animals were summarized as
mean ± SEM. The differences of frequency band changes
between Neurexan and vehicle-treated rats were tested
for significance using the Wilcoxon Mann–Whitney U
test. P < 0.01 was considered significant.
Results
The dose–response relationship between Neurexan and
EEG signatures revealed a predominant effect on δ-, θ-,
and α2-waves in the frontal cortex and reticular forma-
tion (Figure 1). Changes of spectral frequencies were
analyzed between 185 and 245 minutes after oral admin-
istration of a single dose of Neurexan. Although changes
of spectral frequencies were observed at each dosage
(0.25, 0.5, or 1 tablet), most significant changes were
found with 0.5 tablets of Neurexan. At this concentra-
tion, δ-, θ-, and α2-waves were significantly changed in
the frontal cortex when compared with vehicle control
(Figure 1A). Moreover, δ-, θ-, and α2-waves and, in
addition, α1- and β1-waves were significantly altered in
the reticular formation (Figure 1D). In the hippocampus,
only δ-waves were significantly affected by treatment
with 1 tablet of Neurexan (Figure 1B). Between 185 and
245 minutes, no significant change of spectral frequen-
cies could be observed in the striatum (Figure 1C).
Over time, 0.5 tablets of Neurexan significantly chan-
ged most spectral frequencies in the frontal cortex, re-
ticular formation, and striatum when compared with
vehicle control. Effects were predominantly observed on
δ- and θ-waves (Figure 2). In the frontal cortex, δ- and
θ-waves persistently and significantly increased during
the third to fourth hour and during the fourth to fifth
hour after administration, respectively (Figure 2A). In
the reticular formation, δ- and θ-waves significantly
increased during the third to fifth hour and, in addition,
during the first hour after administration (Figure 2D).
Other spectral frequencies were only transiently affected
by Neurexan. In the frontal cortex and reticular forma-
tion, α1-, α2-, and β1-waves were significantly increasedat single experimental intervals. In the striatum, changes
of θ-waves reached significance at two experimental
intervals (third and fifth hours, Figure 2C), whereas no
significant changes were observed in the hippocampus at
this dosage (Figure 2B).
Taken together, Figures 1 and 2 demonstrate that even
a single dose of Neurexan significantly modulated the
EEG signature of several brain areas when compared
with vehicle control. The EEG changes predominantly
affected δ-, θ-, and, to a minor extent, α2-waves in the
frontal cortex and reticular formation.
Discussion
Herein, we demonstrate that the low-dose medication
Neurexan induces significant changes of rat EEG signa-
tures. Neurexan-induced changes predominantly affect
δ- and θ-waves in the frontal cortex and reticular forma-
tion, supporting the fact that Neurexan generally exhi-
bits calming effects.
The rat EEG signature was significantly altered after a
single oral administration of Neurexan when compared
with vehicle control, thus characterizing Neurexan as
psychoactive. Changes were observed in the reticular
formation as early as during the first hour after adminis-
tration. This immediate effect differentiates Neurexan
from other plant-derived drugs against stress-related dis-
orders that are effective as early as 3 hours after admin-
istration [29]. At later time points, EEG signatures of the
frontal cortex and striatum, but not the hippocampus,
were also affected by Neurexan.
After having established the principal evidence of
dose- and time-dependent effects of Neurexan on the
central nervous system, we found a predominant in-
crease of δ- and θ-waves, supporting the calming effect
of Neurexan in general. Earlier publications have
demonstrated that pharmacological interference with
neurotransmitter systems results in changes of distinct
brain waves. Accordingly, changes of δ-waves corres-
pond to interference with the cholinergic system [20].
The fact that enhancing cholinergic transmission in the
reticular formation increases rapid eye movement sleep
in several species [30-32] might, therefore, contribute to
an explanation of the beneficial effects of Neurexan on
sleep disturbance [16]. According to previous studies
[21,33], Neurexan-induced changes of α2-waves can be
interpreted as inactivation of the dopaminergic system,
whereas increases of θ-waves could be related to inter-
ference with the norepinephrine α2 receptor, leading to
sedation [22].
The effects on EEG signatures in rats have been
demonstrated for several different synthetic and plant-
derived psychoactive substances, and, more important,
the same method of EEG recording was used in these
studies [20,24,28]. We were, therefore, able to
Figure 1 Effects of control and 0.25, 0.50, and 1 tablet of Neurexan on the spectral frequencies in four rat brain areas (frontal cortex
[A], hippocampus [B], striatum [C], and reticular formation [D]). The encephalographic (EEG) signatures were obtained between 185 and
245 minutes after oral administration of a single dose of Neurexan. Changes of δ-, θ-, α1-, α2-, β1-, and β2-waves are presented as percentage of
predrug baseline. The data of eight rats are summarized as mean± SEM. Significant differences to vehicle controls (0.9% NaCl) are indicated by
asterisks (P< 0.01).
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frequency bands in four rat brain areas with those of
other substances. It might not be scientifically adequate
to draw direct conclusions from these comparisons, but
several similarities between Neurexan and Valeriana or
Passiflora could be found (data not shown).
Both Valeriana and Passiflora are present in Neurexan,
although at a far smaller concentration. Several clinical
trials have demonstrated that Valeriana effectively treats
insomnia mostly by reducing sleep latency and improv-
ing sleep quality. In two double-blind and placebo-
controlled studies, single doses between 400 and 900 mg
significantly improved sleep latency and sleep quality
when compared with placebo [34,35]. In two rando-
mized, double-blind studies, the effects of Valeriana
(600 mg/d) on insomnia were comparable to those of
Oxazepam [36,37]. Interestingly, a high dosage of
Valeriana (1500 mg Valeriana in combination with
360 mg hops) particularly increased δ-waves in humansubjects [38]. However, the concentration of Valeriana in
Neurexan is far lower (0.6 mg valerianate of zinc D4 per
tablet), but Neurexan has been as effective as Valeriana-
based therapies for the treatment of mild to moderate
insomnia [16]. Either highly diluted valerianate of zinc
might be as effective as high-dose Valeriana or, more
probably, the combination of valerian ate of zinc with
other components of Neurexan synergistically mediates
calming effects.
The second comparator drug generating a similar EEG
signature such as Neurexan, Passiflora, exerts anxiolytic
effects in mice [39,40] and humans [10-12]. In a double-
blind, placebo-controlled trial, Passiflora has been as ef-
fective as benzodiazepine in eliminating anxiety symp-
toms [10]. Doses of 10 mg/kg body weight were effective
in mice [39]. In our experiments, the reference drug
Passiflora was applied at a dose of 100 mg/kg and pre-
dominantly increased θ-activity in the frontal cortex and
striatum (data not shown). Likewise, 1200 mg of
Figure 2 Time course of the effects of 0.5 tablets of Neurexan on the spectral frequencies in four rat brain areas (frontal cortex [A],
hippocampus [B], striatum [C], and reticular formation [D]). The electroencephalographic (EEG) signatures were obtained during five
experimental intervals of 1 hour (1, 2, 3, 4, and 5 hours). Changes of δ-, θ-, α1-, α2-, β1-, and β2-waves are presented as percentage of predrug
baseline. The data of eight rats are summarized as mean± SEM. Significant differences to vehicle controls (0.9% NaCl) are indicated by asterisks
(P< 0.01).
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increased δ-waves in patients with sleep disorders [41].
Concerning this influence on EEG activity, Neurexan con-
taining low-dose Passiflora seems to be comparably effect-
ive as the high-dose comparator drug.
We recognize two major limitations of our study. First,
the number of animals in our study was relatively small,
but the sample size was sufficient to detect significant
effects (P < 0.01) on the EEG signature in rats. Second,
our results are rather descriptive and need to be corre-
lated with the effects of Neurexan on human subjects,
even if the translatability of results across mammalian
species might be widely accepted [18]. However, one ob-
jective of our study was to demonstrate an effect of this
low-dose and multicomponent medication on the central
nervous system, providing a starting point for further re-
search. Correlation with the effectiveness of Neurexan
on moderate insomnia and nervousness has already been
provided by two observational studies [16,17]. Moreover,
a double-blind, placebo-controlled trial is conducted toevaluate the psychophysiological effects of Neurexan on
human subjects in more detail.
Conclusion
In summary, the current study demonstrated that the
multicomponent, low-dose medication, Neurexan, influ-
ences neuronal activity in particular brain areas, thereby
suggesting that the drug has calming effects. The simi-
larity of Neurexan with other medications with known
calming effects suggests that the combination of the
lower concentrated components of Neurexan exerts an
additive and synergistic effect on neuroactivity. It can be
speculated that Neurexan has beneficial effects for
patients with stress-related disorders. Moreover, this re-
port demonstrates that EEG signatures are valid biomar-
kers for the psychoactivity of multicomponent, low-dose
medications, such as Neurexan. The outcome gives
guidance for further scientific investigations of that drug,
to identify the working mechanism and its efficacy in
more detail.
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